{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T23:03:00Z","timestamp":1777417380009,"version":"3.51.4"},"reference-count":21,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2007,1,1]],"date-time":"2007-01-01T00:00:00Z","timestamp":1167609600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Medical Hypotheses"],"published-print":{"date-parts":[[2007,1]]},"DOI":"10.1016\/j.mehy.2006.07.017","type":"journal-article","created":{"date-parts":[[2006,9,26]],"date-time":"2006-09-26T08:02:59Z","timestamp":1159257779000},"page":"1144-1146","source":"Crossref","is-referenced-by-count":10,"title":["Semax, an analogue of adrenocorticotropin (4\u201310), is a potential agent for the treatment of attention-deficit hyperactivity disorder and Rett syndrome"],"prefix":"10.1016","volume":"68","author":[{"given":"Shih-Jen","family":"Tsai","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.mehy.2006.07.017_bib1","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1111\/j.1469-7610.1989.tb00236.x","article-title":"Ontario child health study: prevalence of attention deficit disorder with hyperactivity","volume":"30","author":"Szatmari","year":"1989","journal-title":"J Child Psychol Psychiatry"},{"key":"10.1016\/j.mehy.2006.07.017_bib2","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/S0166-4328(01)00431-4","article-title":"Dopamine dysfunction in AD\/HD: integrating clinical and basic neuroscience research","volume":"130","author":"Solanto","year":"2002","journal-title":"Behav Brain Res"},{"key":"10.1016\/j.mehy.2006.07.017_bib3","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.coph.2004.10.001","article-title":"Stimulants: use and abuse in the treatment of attention deficit hyperactivity disorder","volume":"5","author":"Fone","year":"2005","journal-title":"Curr Opin Pharmacol"},{"key":"10.1016\/j.mehy.2006.07.017_bib4","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1017\/S1092852900018460","article-title":"Non-stimulant treatment of attention-deficit\/hyperactivity disorder","volume":"8","author":"Pliszka","year":"2003","journal-title":"CNS Spectr"},{"key":"10.1016\/j.mehy.2006.07.017_bib5","first-page":"420","article-title":"A nootropic adrenocorticotropin analog 4\u201310-semax (l5 years experience in its design and study)","volume":"47","author":"Asmarin","year":"1997","journal-title":"Zh Vyssh Nerv Deiat Im I P Pavlova"},{"key":"10.1016\/j.mehy.2006.07.017_bib6","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1023\/A:1025177812262","article-title":"The heptapeptide SEMAX stimulates BDNF expression in different areas of the rat brain in vivo","volume":"391","author":"Dolotov","year":"2003","journal-title":"Dokl Biol Sci"},{"key":"10.1016\/j.mehy.2006.07.017_bib7","first-page":"105","article-title":"Design and investigation of an ACTH (4\u201310) analogue lacking d-amino acids and hydrophobic radicals","volume":"16","author":"Ashmarin","year":"1995","journal-title":"Neurosci Res Commun"},{"key":"10.1016\/j.mehy.2006.07.017_bib8","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1002\/(SICI)1520-6769(199609)19:2<115::AID-NRC171>3.0.CO;2-B","article-title":"Synthetic ACTH analogue Semax displays nootropic-like activity in humans","volume":"19","author":"Kaplan","year":"1996","journal-title":"Neurosci Res Commun"},{"key":"10.1016\/j.mehy.2006.07.017_bib9","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1016\/S0306-9877(03)00052-5","article-title":"Attention-deficit hyperactivity disorder and brain-derived neurotrophic factor: a speculative hypothesis","volume":"60","author":"Tsai","year":"2003","journal-title":"Med Hypotheses"},{"key":"10.1016\/j.mehy.2006.07.017_bib10","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1038\/sj.mp.4001696","article-title":"Association of the paternally transmitted copy of common Valine allele of the Val66Met polymorphism of the brain-derived neurotrophic factor (BDNF) gene with susceptibility to ADHD","volume":"10","author":"Kent","year":"2005","journal-title":"Mol Psychiatry"},{"key":"10.1016\/j.mehy.2006.07.017_bib11","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1016\/j.mehy.2006.06.025","article-title":"Attention-deficit hyperactivity disorder may associate with decreased central brain-derived neurotrophic factor activity: clinical and therapeutic implications","volume":"68","author":"Tsai","year":"2007","journal-title":"Med Hypotheses"},{"key":"10.1016\/j.mehy.2006.07.017_bib12","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/S0304-3940(01)01994-2","article-title":"Rapid induction of neurotrophin mRNAs in rat glial cell cultures by Semax, an adrenocorticotropic hormone analog","volume":"308","author":"Shadrina","year":"2001","journal-title":"Neurosci Lett"},{"issue":"Suppl. 1","key":"10.1016\/j.mehy.2006.07.017_bib13","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1111\/j.1471-4159.2006.03658.x","article-title":"Semax, an analogue of adrenocorticotropin (4\u201310), binds specifically and increases levels of brain-derived neurotrophic factor protein in rat basal forebrain","volume":"97","author":"Dolotov","year":"2006","journal-title":"J Neurochem"},{"key":"10.1016\/j.mehy.2006.07.017_bib14","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1016\/j.mehy.2003.12.060","article-title":"Supportive neurodevelopmental evidence for ADHD as a developmental disorder","volume":"64","author":"Panzer","year":"2005","journal-title":"Med Hypotheses"},{"key":"10.1016\/j.mehy.2006.07.017_bib15","first-page":"122","article-title":"Dependence of long-lasting effects of the ACTH(4\u201310) analogue semax on the time of its neonatal administration","volume":"91","author":"Sebentsova","year":"2005","journal-title":"Ross Fiziol Zh Im I M Sechenova"},{"key":"10.1016\/j.mehy.2006.07.017_bib16","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1111\/j.1741-4520.2003.tb01035.x","article-title":"The dopaminergic system in attention deficit\/hyperactivity disorder","volume":"43","author":"Ohno","year":"2003","journal-title":"Congenit Anom"},{"key":"10.1016\/j.mehy.2006.07.017_bib17","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1007\/s11064-005-8826-8","article-title":"Semax, an ACTH(4\u201310) analogue with nootropic properties, activates dopaminergic and serotoninergic brain systems in rodents","volume":"30","author":"Eremin","year":"2005","journal-title":"Neurochem Res"},{"key":"10.1016\/j.mehy.2006.07.017_bib18","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1038\/13810","article-title":"Rett syndrome is caused by mutations in X-linked MECP2, encoding methyl-CpG-binding protein 2","volume":"23","author":"Amir","year":"1999","journal-title":"Nat Genet"},{"key":"10.1016\/j.mehy.2006.07.017_bib19","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.neuron.2005.12.027","article-title":"The disease progression of mecp2 mutant mice is affected by the level of BDNF expression","volume":"49","author":"Chang","year":"2006","journal-title":"Neuron"},{"key":"10.1016\/j.mehy.2006.07.017_bib20","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1016\/j.mehy.2006.02.029","article-title":"Lithium and antidepressants: Potential agents for the treatment of Rett syndrome","volume":"67","author":"Tsai","year":"2006","journal-title":"Med Hypotheses"},{"key":"10.1016\/j.mehy.2006.07.017_bib21","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1038\/85906","article-title":"Deficiency of methyl-CpG binding protein-2 in CNS neurons results in a Rett-like phenotype in mice","volume":"27","author":"Chen","year":"2001","journal-title":"Nat Genet"}],"container-title":["Medical Hypotheses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0306987706005391?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0306987706005391?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,1,12]],"date-time":"2019-01-12T18:52:40Z","timestamp":1547319160000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0306987706005391"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,1]]},"references-count":21,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2007,1]]}},"alternative-id":["S0306987706005391"],"URL":"https:\/\/doi.org\/10.1016\/j.mehy.2006.07.017","relation":{},"ISSN":["0306-9877"],"issn-type":[{"value":"0306-9877","type":"print"}],"subject":[],"published":{"date-parts":[[2007,1]]}}}